ABSTRACT
Background: Aging is an inevitable biological change, but understanding the process of aging of face is important to customize the treatment options for facial rejuvenation. Evidence-based estimation of global facial aging is necessary for the validation of various treatment modalities. Aims: Classification and implementation of a scoring system for aging face based upon volume loss and surface changes as evident by drooping of different areas of the face and appearance of fine and deep wrinkles, respectively, and to apply this drooping–wrinkles classification on 54 participants to evaluate and understand the validity of scoring. Methods: An observational study was conducted, and scores were calculated based on 13 parameters (7 areas of drooping and 6 areas of wrinkles on the face) at Aura Skin Institute, Chandigarh, India. Accordingly, age was divided in different age groups followed by clinical estimation of facial age and calculation of scores. Results: According to our classification and scoring system, 61% (33 out of 54) of the participants were correlated with their chronological age group. Out of the remaining 21 (39%) participants who were aging faster, 13 (24%) were in the age group of 25–35 years. Approximately one-fourth of the patients in the age groups 36–45 and 46–55 years were aging faster. Only 1 patient had scores showing younger age in comparison to chronological age. Overall, there was a good correlation between the calculated score and the chronological age of patients. Moreover, a gradual increase in scores was noticed with increasing age groups. Conclusions: This is a new clinical classification and scoring system for facial age which is much easier to apply in daily clinical practice for easy calculation of baseline scores and customizing their antiaging treatment options. Moreover, it will also make it easier to compare the efficacy of treatment in their future follow-ups. The limitation of this study is that it has been proposed for all skin types but validation has been done only for Indian participants.
ABSTRACT
Syphilis does not only affect the individual but is also a public health problem. It also increases risk of HIV infection and can cause lifelong morbidity among children born to infected mothers. High risk behaviour like multiple sex partners and unsafe injection practices not only increases chances of acquiring HIV but increase the risk for HBV and HCV transmission. This study was undertaken to study the seroprevalence of Syphilis and co-infection with HIV, HBVand HCVin a tertiary care hospital of Mumbai. Material and Methods: A total of 4160 blood samples received in the Regional STI Training, Research and Reference Laboratory, Department of Microbiology, Mumbai from patients attending the Suraksha clinic, referrals from high risk cases from peripheral hospitals, various STI clinics and ART patients were received from January to December 2016. Syphilis testing was performed using VDRL antigen from Institute of Serology, Kolkata. All the sera reactive in qualitative and quantitative VDRL test were confirmed for antitreponemal antibodies by TPHA test. Biological false positives (BFP) estimated Testing for HIV was done as per National guidelines. Hepatitis B surface Antigen and Hepatitis C virus antibody testing were done using ELISAmethods. Results: The seroprevalence of Syphilis in our study was 3% with BFP of 0.7 %. HIV, HBV and HCV seropositivity in the study was 6.63%, 3.36% and 1.73% respectively. The co-infection rate of HIV, HBV and HCV with Syphilis in the study was 0.21%, 0.16% and 0.07% respectively. Coinfection of HBVand HCVwith HIVwas 0.28% and 0.26% respectively. HBVand HCVco-infection was 0.04%. Conclusion: Public health interventions should be carried out to promote awareness of syphilis among physicians and populations at risk in India. The increased risk of acquiring HBV, HCVand HIVin STI clinic attendees warrants screening the high-risk population for these viral infections.